Tourmaline Bio Future Growth
Future criteria checks 0/6
Tourmaline Bio's earnings are forecast to decline at 13.4% per annum while its annual revenue is expected to grow at 70.3% per year. EPS is expected to grow by 21.8% per annum.
Key information
-13.4%
Earnings growth rate
21.8%
EPS growth rate
Biotechs earnings growth | 24.5% |
Revenue growth rate | 70.3% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 22 Mar 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 10 | -98 | -69 | -63 | 6 |
12/31/2025 | 10 | -81 | -68 | -84 | 6 |
12/31/2024 | N/A | -66 | -67 | -72 | 6 |
12/31/2023 | N/A | -42 | -28 | -28 | N/A |
9/30/2023 | N/A | -34 | -23 | -23 | N/A |
6/30/2023 | N/A | -31 | -19 | -19 | N/A |
3/31/2023 | N/A | -27 | -15 | -10 | N/A |
12/31/2022 | N/A | -20 | -12 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TRML is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TRML is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TRML is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TRML is forecast to have no revenue next year.
High Growth Revenue: TRML is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TRML's Return on Equity is forecast to be high in 3 years time